arGEN-X SE ADR (ARGX) News
Filter ARGX News Items
ARGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARGX News Highlights
- For ARGX, its 30 day story count is now at 10.
- Over the past 14 days, the trend for ARGX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about ARGX are SKIN, ADD and DOW.
Latest ARGX News From Around the Web
Below are the latest news stories about ARGENX SE that investors may wish to consider to help them evaluate ARGX as an investment opportunity.
UPDATE 2-European shares end slightly higher ahead of Christmas holidayEuropean stocks closed with a whimper on Friday, as softer-than-expected U.S. inflation data offset losses in sportwear makers and China-exposed stocks ahead of the Christmas holiday weekend. The pan-European STOXX 600 index edged up 0.1% and notched its sixth week of gains in a row - a winning streak that was last seen in December 2022. European markets will be shut on Monday for Christmas. |
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-offImmunovant unveiled promising results for a Graves' disease treatment on Thursday, helping IMVT stock reverse a recent downfall. |
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Studyargenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls. |
Why Is Argenx (ARGX) Stock Down 25% Today?Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock. |
Stock Market Does Sharp About-Face; Dow Breaks Win StreakStock market indexes unexpectedly reversed course in afternoon trading Wednesday, sending the major indexes lower by more than 1%. The Dow Jones Industrial Average couldn't add to its nine-day win streak after reaching all-time highs. |
Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, VyvgartArgenx stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study. |
Argenx autoimmune drug study fails in blow to expansion hopesThe Dutch biotech’s star product has lost some luster after a second failed Phase 3 trial in two months, this time for a skin condition called pemphigus. |
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indicationUpdate on BALLAD study GO/NO GO decisionConference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm CET) Regulated Information – Inside Information December 20, 2023, 7:00am CET AMSTERDAM, THE NETHERLANDS — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced t |
argenx SE’s (ARGX) Share Price Increased By 28% Due to Several FactorsTimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy outperformed the Russell Midcap Growth Index and returned -4.11% (net) while the index return was -5.22%. The third quarter saw a decline in […] |
30 Largest Pharmaceutical Companies in the WorldIn this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world’s leading pharmaceutical companies became the center of attention for people all over the world as a […] |